Pipeline — registered trials by phase
Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records
— · Non-Hematologic Malignancy · Completed · est. 2020-02-01
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
— · Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma · Recruiting · est. 2030-08
Noninvasive vs. Invasive Lung Evaluation
— · Non-Small Cell Lung Cancer · Completed · est. 2020-11-23
Shield Post-Approval Study Protocol
— · Colo-rectal Cancer · Recruiting · est. 2030-09-01
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
— · Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer · Recruiting · est. 2030-12-30
Screening for High Frequency Malignant Disease
— · Lung Cancer · Active Not Recruiting · est. 2026-12-31
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
— · Colorectal Cancer · Active Not Recruiting · est. 2024-03-20
Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer
— · Advanced Breast Cancer · Completed · est. 2022-03-17
Decision Counseling and Follow-up for Shield+ Patients
— · Colo-rectal Cancer · Not Yet Recruiting · est. 2027-12
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Guardant Health is lead sponsor; 9 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- S-3ASR2026-07-30S-3ASR
- 10-Q2026-07-30Quarterly report
- 8-K2026-07-30Current report (material event)
- SCHEDULE 13G/A2026-07-28SCHEDULE 13G/A
- 8-K2026-06-18Current report (material event)
- SCHEDULE 13G2026-05-15SCHEDULE 13G
- 10-Q2026-05-07Quarterly report
- 8-K2026-05-07Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- ARS2026-04-28Annual report to holders
- DEFA14A2026-04-28DEFA14A
- DEF 14A2026-04-28Proxy statement
- 8-K2026-04-27Current report (material event)
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- S-82026-02-20Employee stock plan
- 10-K2026-02-19Annual report
- 8-K2026-02-19Current report (material event)
- 8-K2026-01-12Current report (material event)
- 8-K2025-11-07Current report (material event)
- 424B52025-11-06Prospectus (offering)
- FWP2025-11-05FWP
- FWP2025-11-04FWP
- 424B52025-11-04Prospectus (offering)
- 10-Q2025-10-29Quarterly report
- 8-K2025-10-29Current report (material event)
- 8-K2025-09-24Current report (material event)
- 8-K2025-09-15Current report (material event)
- 10-Q2025-07-30Quarterly report
- 8-K2025-07-30Current report (material event)
- 8-K2025-06-20Current report (material event)
- SCHEDULE 13G/A2025-05-15SCHEDULE 13G/A
- 10-Q2025-04-30Quarterly report
- 8-K2025-04-30Current report (material event)
- ARS2025-04-29Annual report to holders
- DEFA14A2025-04-29DEFA14A
- DEF 14A2025-04-29Proxy statement
- SCHEDULE 13G/A2025-04-17SCHEDULE 13G/A
- 8-K2025-04-09Current report (material event)
- S-82025-02-24Employee stock plan
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.